Side-by-side · Research reference
MOTS-cvsRetatrutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongReviewed16/68 cited
BPhase 2Reviewed10/41 cited
MOTS-c
Mitokine · Mitochondria-Encoded
SQ · Variable · 2–3×/week
Retatrutide
Triple-receptor agonist · Phase 3
SQ · Abdomen · Once weekly
01Mechanism of Action
Parameter
MOTS-c
Retatrutide
Primary target
Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015
GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023
Pathway
Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023
Downstream effect
Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015
Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023
Origin
Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021
Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023
Antibody development
—
—
02Dosage Protocols
Parameter
MOTS-c
Retatrutide
Standard dose
5–10 mg / weekLee 2015
Experimental, extrapolated from animal data. No human RCT-derived dose.
12 mg / week (max efficacy)Jastreboff 2023
Phase 2 trial dose. Phase 3 dosing TBD.
Frequency
2–3× per week
Short half-life may necessitate more frequent dosing for saturation.
Once weekly
Lower / starter dose
2.5–5 mg / week
Recommended due to limited human data.
—
Evidence basis
Animal + anecdotalLee 2015Reynolds 2021A first-in-human phase 1 study 2021
Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.
Phase 2 trial; Phase 3 ongoingJastreboff 2023
Duration
4–12 weeks (experimental)
Optimal cycle length unknown.
Indefinite for chronic indication (presumed)
Reconstitution
Bacteriostatic water, 1–2 mL
10 mg/mL at 1 mL.
Investigational; not commercially available
Timing
Pre-workout or fasted state preferred
Activity-context amplifies AMPK response.
Any time of day
Half-life
Minutes to hours (estimated)
Systemically unstable; native MOTS-c PK in humans not fully characterised.
~6 days (estimated from class)
Titration schedule
—
2 mg → 4 mg → 8 mg → 12 mg over 16 weeks
03Metabolic / Fat Loss Evidence
Parameter
MOTS-c
Retatrutide
Primary fat target
Diet-induced / metabolic obesity; systemic fat utilization
—
Quantified reduction
Significant HFD fat gain ↓Lee 2015
Murine models, dose-dependent (5 & 15 mg/kg).
—
IGF-1 impact
No direct IGF-1 pathway; AMPK-mediated
—
Effect on lean mass
High dose significantly ↑ lean mass in mice
—
Triglycerides
AMPK-driven FA oxidation suggests TG benefit (not directly measured)
—
Effect reversibility
Unknown — no long-term follow-up data
—
Key publication
Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015Reynolds 2021Kim 2018
—
04Side Effects & Safety
Parameter
MOTS-c
Retatrutide
Injection site reaction
Mild irritation (reported)
—
Fluid retention / Edema
Not reported
—
Cardiovascular
Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats
—
Cancer risk
Contradictory data — some models suggest pro-proliferative effects
—
CNS / Neurological
Insomnia, headache (anecdotal reports)
—
GI symptoms
Nausea, stomach discomfort (reported)
Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid — insufficient safety data
Avoid (insufficient data)
Evidence quality
Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021
—
Glucose handling
—
Glycemic improvement; rare hyperglycemia from glucagon component
Pancreatitis risk
—
Class warning
Thyroid C-cell tumours
—
Class warning (presumed)
Absolute Contraindications
MOTS-c
- ·Pregnancy / breastfeeding (insufficient data)
Retatrutide
- ·MTC personal or family history (presumed class effect)
- ·Pregnancy / breastfeeding
Relative Contraindications
MOTS-c
- ·Active cancer or cancer predisposition
- ·AMPK pathway deficiency (efficacy nullified)
- ·Use with cancer-promoting medications (theoretical)
Retatrutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe cardiovascular disease (HR signal)
05Administration Protocol
Parameter
MOTS-c
Retatrutide
1. Reconstitution
Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.
Investigational peptide. Research vials reconstituted with bacteriostatic water per label.
2. Injection site
Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.
Once weekly, same day.
4. Storage
Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.
Refrigerate 2–8 °C. Light-protected.
5. Needle
27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.
27–31G, 4–8 mm insulin syringe.
06Stack Synergy
MOTS-c
+ Ipamorelin
ModerateMOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.
- MOTS-c
- 5 mg SQ · pre-workout (2–3×/wk)
- Ipamorelin
- 200–300 mcg SQ · pre-sleep (daily)
- Primary benefit
- Metabolic flexibility + GH recovery + ROS reduction
Retatrutide
— no documented stacks